Sailing past the $2B mark, Flagship sets course for $500M-plus biotech fund, unveils a new startup
Over the past few years Flagship Pioneering has gambled hundreds of millions of dollars on some of the most intriguing bets in big science, recruiting some big names in biopharma to steer these ventures forward. And now Flagship chief Noubar Afeyan and his team are looking for more than $500 million more to double down on that strategy.
Flagship posted an SEC filing that has pencilled in a $500 million goal for Fund VI, but that’s likely the threshold figure they’ll shoot to surpass to underscore their investors’ appetite for new technology in drug development.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
